2017 Fourth Quarter and Full Year Financial Results
Revenue for the fourth quarter of 2017 totaled $7.6 million, up from $7.3 million in the prior year quarter. Recurring revenue was $6.9
million in the quarter, up 7% from $6.5 million in the prior year quarter. Recurring revenue benefited from 7% year-over-year growth in global procedures, with all major geographies contributing to the acceleration in procedure growth.
Recurring revenue for the full year 2017 of $26.9 million represents a 2% increase above the $26.4 million recorded for the same period in 2016. Procedures for the full year 2017 grew 3% over the full year 2016, the first year of annual
procedure growth since 2012. System revenue in the fourth quarter was $0.6 million, down from $0.8 million in the prior year quarter. System revenue of $4.3 million for the full year 2017 was down from $5.8 million in
2016, primarily reflecting the expiration of an Odyssey distribution agreement and the timing of Niobe system installations in 2016.
fourth quarter of 2017, Stereotaxis recorded a non-cash inventory-related charge of $3.8 million to systems cost of goods sold. Including this charge, gross margin in the quarter
was $2.2 million, or 29% of revenue, versus $5.3 million, or 73% of revenue, in the fourth quarter of 2016. Excluding the non-cash inventory-related charge, gross margin for the fourth
quarter would have been 80%.
Operating expenses in the fourth quarter were $5.9 million, down 20% from $7.4 million in the prior year
quarter. The reduction in operating expenses continues to reflect the year-over-year impact of lower executive compensation and more efficient management of expenses across the organization, but does not represent any material changes in the
organizations personnel, infrastructure or capabilities. Operating loss in the fourth quarter was $(3.7) million, compared to $(2.1) million in the prior year fourth quarter. Excluding the
non-cash inventory-related charge, the company would have shown an operating profit of $0.1 million. Net loss for the fourth quarter of $(2.6) million includes $1.2 million of mark-to-market warrant revaluation income. Excluding the mark-to-market warrant revaluation
income and inventory-related charge, the Company would have reported net income of less than $0.1 million for the quarter. Cash burn for the fourth quarter was $0.8 million.
Cash Balance and Liquidity
At December 31,
2017, Stereotaxis had cash and cash equivalents of $3.7 million, no debt, and $2.7 million in unused borrowing capacity on its revolving credit facility, for total liquidity of $6.4 million. In a separate
press release this morning Stereotaxis announced that it has raised $10.0 million from the non-dilutive induced early exercise of outstanding warrants. On a
pro-forma basis, including the capital from the exercise of these warrants, Stereotaxis had $13.7 million in cash and cash equivalents and no debt as of December 31, 2017.
Full Year 2018 Expectations
2018 with a solid plan for progress and a healthy financial foundation to execute on the plan. Operating expenses are expected to moderately increase in 2018, primarily driven by R&D spending on strategic innovation initiatives. While the
benefits of these initiatives are unlikely to impact revenue in 2018 they are expected to meaningfully contribute in 2019 and beyond. Stereotaxis balance sheet will allow the Company to deliver on its commercial and innovation initiatives over
the coming years and reach profitability without the need for additional financings.